Regeneron Pharmaceuticals, Inc. or United Therapeutics Corporation: Who Invests More in Innovation?

Biotech Giants' R&D Race: Regeneron vs. United Therapeutics

__timestampRegeneron Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 20141271353000242549000
Thursday, January 1, 20151620577000245098000
Friday, January 1, 20162052295000147600000
Sunday, January 1, 20172075142000264600000
Monday, January 1, 20182186100000357900000
Tuesday, January 1, 201930366000001182600000
Wednesday, January 1, 20202735000000357700000
Friday, January 1, 20212908100000540100000
Saturday, January 1, 20223592500000322900000
Sunday, January 1, 20234439000000408000000
Monday, January 1, 20245132000000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: A Tale of Two Biotech Giants

In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Regeneron Pharmaceuticals, Inc. and United Therapeutics Corporation have been at the forefront of this race. From 2014 to 2023, Regeneron consistently outpaced United Therapeutics in research and development (R&D) spending, investing nearly 6 times more on average. In 2023, Regeneron's R&D expenses soared to a staggering $4.4 billion, marking a 250% increase from 2014. Meanwhile, United Therapeutics' investment peaked at $1.18 billion in 2019, a significant leap from its 2014 expenditure. This trend underscores Regeneron's commitment to innovation, positioning it as a leader in the biotech industry. As these companies continue to push the boundaries of medical science, their R&D investments will be crucial in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025